AKESO

Prezzo AKESO 09926.HK

AKESO
$0
+$0(0,00%)
Nessun dato

*Data last updated: 2026-04-28 20:38 (UTC+8)

As of 2026-04-28 20:38, AKESO 09926.HK (AKESO) is priced at $0, with a total market cap of --, a P/E ratio of 0,00, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of --. Over the past 52 weeks, AKESO has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

AKESO Key Stats

P/E Ratio0,00
Dividend Yield (TTM)0,00%
Shares Outstanding0,00

AKESO 09926.HK (AKESO) FAQ

What's the stock price of AKESO 09926.HK (AKESO) today?

x
AKESO 09926.HK (AKESO) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for AKESO 09926.HK (AKESO)?

x

What is the price-to-earnings (P/E) ratio of AKESO 09926.HK (AKESO)? What does it indicate?

x

What is the market cap of AKESO 09926.HK (AKESO)?

x

What is the most recent quarterly earnings per share (EPS) for AKESO 09926.HK (AKESO)?

x

Should you buy or sell AKESO 09926.HK (AKESO) now?

x

What factors can affect the stock price of AKESO 09926.HK (AKESO)?

x

How to buy AKESO 09926.HK (AKESO) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Hot Posts su AKESO 09926.HK (AKESO)

SelfRugger

SelfRugger

04-26 14:49
This is a paid press release. Contact the press release distributor directly with any inquiries. CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type ========================================================================================================================================================================================= Research and Markets Thu, February 19, 2026 at 1:00 AM GMT+9 3 min read Company Logo _The CTLA-4 inhibitors market offers promising opportunities in cancer immunotherapy, with over 40 companies developing 50+ drugs globally. Key opportunities include leveraging synergistic combinations, advancing bispecific antibodies, targeting tumor microenvironments, and overcoming immune resistance in hard-to-treat cancers._ Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "CTLA-4 Inhibitors - Competitive Landscape, 2026" has been added to ** ResearchAndMarkets.com's** offering. This report offers a comprehensive overview of more than 40 companies and over 50 drugs within the CTLA-4 inhibitors competitive landscape. It covers therapeutics assessment by product type, stage, route of administration, and molecule type, while also highlighting inactive pipeline products. Geographically, the report provides a global outlook on the cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors landscape. CTLA-4 is a major negative regulator of T cell activation. Inhibiting this negative regulation boosts adaptive immunity, showing efficacy in multiple cancer models. CTLA-4 inhibitors are vital in cancer immunotherapy, often working synergistically with other treatments to enhance anti-tumor responses. The report encompasses a detailed commercial assessment of drugs and key collaborations, including licensing, acquisitions, and industry partnerships. It provides a thorough analysis of unmet needs, pipeline assessments, and strategic partnerships within the CTLA-4 inhibitors market. **Report Highlights** * In March 2023, Molecular Templates, Inc. received FDA clearance to proceed with clinical testing of its MT-8421 ETB program targeting CTLA-4 for patients with relapsed/refractory solid tumors. Initial data displayed promise in immune regulation. * In October 2022, the FDA approved the CTLA-4 checkpoint inhibitor tremelimumab for use in a combination immunotherapy regimen for hepatocellular cancer. * As of August 2022, Biocytogen Pharmaceuticals and TRACON Pharmaceuticals obtained FDA approval for a Phase 1/2 clinical study of YH001 with envafolimab and doxorubicin for sarcoma patients. * Akeso, Inc. gained approval for its bi-specific antibody, Cadonilimab (AK104), from China's NMPA in June 2022, targeting cervical cancer patients with prior chemotherapy exposure. * Xencor, Inc. presented promising Phase 2 study results of vudalimab in prostate cancer patients, with some achieving stable disease status as of November 2022. * In January 2022, Vetigenics revealed preclinical data supporting their canine anti-CTLA4 antibody for cancer treatment in dogs, showcasing effective immune response stimulation. Story continues **Company and Product Profiles: Marketed and Pipeline Therapies** * **Bristol Myers Squibb**: Known for their product, Yervoy, a monoclonal antibody targeting CTLA-4, approved for melanoma therapy and expanding across multiple tumor types. * **Alphamab Oncology**: Their bispecific antibody KN046 is progressing through clinical trials in multiple tumor types, with promising survival data. * **Innovent Biologics**: Developing IBI-310 for various cancers, currently in Phase III trials for hepatocellular carcinoma treatment. * **Agenus**: Focuses on botensilimab, showing responses in previously resistant tumors, advancing through Phase 2 trials for multiple cancers. * **Harbour BioMed**: Their innovative product Porustobart has shown promising results in Phase I trials for several solid tumors. **Key Players** * Innovent Biologics, Alphamab Oncology, Agenus * Harbour BioMed, AstraZeneca, Alpine Immune Sciences * Henlix Biotech, DotBio, TrueBinding * Ocean Biomedical, Xencor, Molecular Templates * Akeso, Inc., TRACON Pharmaceuticals, Biocytogen Pharmaceuticals **Key Products** * KN046, IBI-310, Botensilimab, Porustobart * Tremelimumab, Davoceticept, HLX-13 * DB-002, IMT-400, OCX 909 * Vudalimab, MT-8421, AK104, YH001 **Companies Featured** * Innovent Biologics * Alphamab Oncology * Agenus * Harbour BioMed * AstraZeneca * Alpine Immune Sciences * Henlix Biotech * DotBio * TrueBinding * Ocean Biomedical * Xencor * Molecular Templates * Akeso, Inc. * TRACON Pharmaceuticals, Inc. * Biocytogen Pharmaceuticals For more information about this report visit **About ResearchAndMarkets.com** ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0